Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
Severe allergic eosinophilic asthma can be characterized by inadequate control, despite the regular use of high dosages of inhaled corticosteroids/long-acting β 2 -adrenergic agonists combinations, and the very frequent utilization of oral corticosteroids. Therefore, under these circumstances, an ad...
Main Authors: | Corrado Pelaia, Maria Teresa Busceti, Alessandro Vatrella, Marco Ciriolo, Eugenio Garofalo, Claudia Crimi, Rosa Terracciano, Nicola Lombardo, Girolamo Pelaia |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-02-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X20906963 |
Similar Items
-
Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
by: Corrado Pelaia, et al.
Published: (2021-12-01) -
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
by: Pelaia C, et al.
Published: (2018-03-01) -
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
by: Pelaia C, et al.
Published: (2021-02-01) -
Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
by: Pelaia C, et al.
Published: (2021-09-01) -
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
by: Pelaia C, et al.
Published: (2017-10-01)